

PROJECT NAME:

Management of Patients Receiving Oral Systemic Anti-Cancer Therapy for Advanced Renal Cell Carcinoma. Velindre Cancer Centre, Cardiff, and Ipsen Ltd.

JOINT WORKING PROJECT SUMMARY:

The aim of this project was to develop the management pathway for patients with renal cell carcinoma on oral Vascular Endothelial Growth Factor (VEGF) inhibitors that reduces waiting times and workload in outpatient clinics and improves patient satisfaction.

OUTCOMES ACHIEVED BY THIS PROJECT:

- Delivery of a high-quality patient experience by ensuring that the management and review pathway for patients with renal cell carcinoma on oral VEGF inhibitors is clear, concise and provides equity of care to all patients.
- Service data captured demonstrated the value of new model of care to patients and NHS e.g., improved patient satisfaction, reduced outpatient clinic and pharmacy waiting times, tailored and focussed hospital appointments and increased time with healthcare professionals to discuss treatment.
- A new model for the clinical pathway for patients with renal cell carcinoma having treatment with VEGF inhibitors at Velindre Cancer Centre including a pharmacy education service.
- Despite the COVID-19 pandemic, patients continued to receive treatment and also medicines in their homecare setting.
- The Trust have now committed to resourcing the new pathway as part of the dedicated RCC service.
- Ipsen welcomed the opportunity to collaborate with Velindre Cancer Centre on a significant service development project.

PROJECT START DATE & DURATION: July 2018, 2 years.

Extended following agreement by both parties to March 2021 due to COVID-19.

Project completed March 31st, 2021.